Overview
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
Description
This study will be conducted in 2 parts:
- Part A: Single dose (SD), dose-ranging part in adults with mild to moderate hypertension.
- Part B: SD in adults with mild to moderate hypertension.
Eligibility
Part A: Inclusion Criteria
- Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg
- Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications
Part B: Inclusion Criteria
- Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg
- Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic (if taking) for at least 3 weeks
Both Parts: Exclusion Criteria
- Has known secondary hypertension or serum potassium more than 5 mmol/L
- Has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m\^2
Note: other protocol defined inclusion / exclusion criteria apply
